Get started
Author

Gert De Meerleer

Observed names: De Meerleer, G., De Meerleer, Gert, G DE MEERLEER, G De Meerleer, G O De Meerleer, G de Meerleer, G. DE MEERLEER, G. De Meerleer, GERT DE MEERLEER, Gert De Meerleer*, Gert de Meerleer, Meerleer, Gert De, de Meerleer, Gert
Observed institutions: North Bristol NHS Trust, Emory University, Medical University of Graz, Leiden University Medical Center, Universitair Ziekenhuis Leuven, AZ Groeninge, Ghent University Hospital, Medical University of Sofia, University Medical Center Utrecht, Institute of Oncology Ljubljana, Ghent University, National Institute for Health and Care Excellence, Fred Hutch Cancer Center, University Hospital Zurich, University Hospital of Geneva, IRCCS Ospedale San Raffaele, AZ Maria Middelares, KU Leuven
ORCID: 0000-0002-2891-6235
Observed ORCID: 0000-0002-2891-6235
OpenAlex ID: A5045794019
Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial
2017 · Piet Ost, Dries Reynders, et al. · Journal of Clinical Oncology · 1,359
EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer—2024 Update. Part I: Screening, Diagnosis, and Local Treatment with Curative Intent
2024 · Philip Cornford, Roderick C.N. van den Bergh, et al. · European Urology · 1,246
PDF
Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci
2018 · The Profile Study, Fredrick R. Schumacher, et al. · Nature Genetics · 897
PDF
Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction
2021 · David V. Conti, Burcu F. Darst, et al. · Nature Genetics · 466
EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer. Part II—2024 Update: Treatment of Relapsing and Metastatic Prostate Cancer
2024 · Derya Tilki, Roderick C.N. van den Bergh, et al. · European Urology · 352
PDF
Metastasis-directed Therapy of Regional and Distant Recurrences After Curative Treatment of Prostate Cancer: A Systematic Review of the Literature
2014 · Piet Ost, Alberto Bossi, et al. · European Urology · 350
Evidence behind use of intensity-modulated radiotherapy: a systematic review of comparative clinical studies
2008 · Liv Veldeman, Indira Madani, et al. · The Lancet Oncology · 332
Progression-free Survival Following Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Treatment-naive Recurrence: A Multi-institutional Analysis
2015 · Piet Ost, Barbara Alicja Jereczek-Fossa, et al. · European Urology · 290
Radiotherapy for renal-cell carcinoma
2014 · Gert De Meerleer, Vincent Khoo, et al. · The Lancet Oncology · 280
Long-Term Outcomes and Genetic Predictors of Response to Metastasis-Directed Therapy Versus Observation in Oligometastatic Prostate Cancer: Analysis of STOMP and ORIOLE Trials
2022 · Matthew P. Deek, Kim Van der Eecken, et al. · Journal of Clinical Oncology · 265
PDF
Repeated stereotactic body radiotherapy for oligometastatic prostate cancer recurrence
2014 · Karel Decaestecker, Gert De Meerleer, et al. · Radiation Oncology · 257
PDF
ESTRO ACROP consensus guideline on CT- and MRI-based target volume delineation for primary radiation therapy of localized prostate cancer
2018 · Carl Salembier, Geert Villeirs, et al. · Radiotherapy and Oncology · 249
Salvage Stereotactic Body Radiotherapy for Patients With Limited Prostate Cancer Metastases: Deferring Androgen Deprivation Therapy
2012 · Patrick Berkovic, Gert De Meerleer, et al. · Clinical Genitourinary Cancer · 191
Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence (STOMP): Five-year results of a randomized phase II trial.
2020 · Piet Ost, Dries Reynders, et al. · Journal of Clinical Oncology · 156
Characterizing prostate cancer risk through multi-ancestry genome-wide discovery of 187 novel risk variants
2023 · Anqi Wang, Jiayi Shen, et al. · Nature Genetics · 146
Prostate cancer: ESMO Consensus Conference Guidelines 2012
2013 · A. Horwich, J. Hugosson, et al. · Annals of Oncology · 145
Metastasis-directed Therapy in Treating Nodal Oligorecurrent Prostate Cancer: A Multi-institutional Analysis Comparing the Outcome and Toxicity of Stereotactic Body Radiotherapy and Elective Nodal Radiotherapy
2019 · Elise De Bleser, Barbara Alicja Jereczek-Fossa, et al. · European Urology · 141
Intensity-Modulated Radiotherapy as Primary Therapy for Prostate Cancer: Report on Acute Toxicity After Dose Escalation With Simultaneous Integrated Boost to Intraprostatic Lesion
2008 · Valérie Fonteyne, Geert Villeirs, et al. · International Journal of Radiation Oncology*Biology*Physics · 141
Intensity-modulated radiotherapy as primary treatment for prostate cancer: Acute toxicity in 114 patients
2004 · Gert De Meerleer, Luc Vakaet, et al. · International Journal of Radiation Oncology*Biology*Physics · 138
Prognostic factors influencing prostate cancer‐specific survival in non‐castrate patients with metastatic prostate cancer
2013 · Piet Ost, Karel Decaestecker, et al. · The Prostate · 137
Surveillance or metastasis-directed Therapy for OligoMetastatic Prostate cancer recurrence (STOMP): study protocol for a randomized phase II trial
2014 · Karel Decaestecker, Gert De Meerleer, et al. · BMC Cancer · 136
PDF
Soluble cadherins as cancer biomarkers
2007 · Olivier De Wever, Lara Derycke, et al. · Clinical & Experimental Metastasis · 119
Pattern of Progression after Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Nodal Recurrences
2016 · P. Ost, B.A. Jereczek-Fossa, et al. · Clinical Oncology · 116
EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer-2024 Update. Part I: Screening, Diagnosis, and Local Treatment with Curative Intent
2024 · Cornford, Philip, van den Bergh, Roderick C N, et al. · Zurich Open Repository and Archive (University of Zurich) · 111
Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants
2018 · Tokhir Dadaev, Edward J. Saunders, et al. · Nature Communications · 104
PDF
Works count: 385
Citation count: 12,430
H-index: 50
I10-index: 142
Year
Topic
Type